在Helicobacter pylori根除疗法后,自身免疫性胃炎的增强活性
Takashi Ihara1, Ryoji Kushima2, Ken Haruma3
1Ihara Clinic of Internal Medicine, Kyoto, Japan. tks.nrk.ttr@zeus.eonet.ne.jp.
在患有早期自身免疫性胃炎 (AIG) 的患者中,Helicobacter pylori (H. pylori) 根除疗法导致了缩变化的快速恶化和抗体增加. 这表明,在H. pylori治疗后,AIG活性可能会被揭露或加速.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 自身免疫性胃炎 (AIG) 和Helicobacter pylori (H. pylori) 感染之间的相互作用尚未完全理解.
- 研究这种关系对于理解胃炎的进展和管理至关重要.
研究的目的:
- 检查H. pylori根除治疗对早期自身免疫性胃炎的影响.
- 观察随着时间的推移,AIG和H. pylori胃炎的动态变化.
主要方法:
- 一个老年患者的病例研究,同时存在早期AIG和活跃的H. pylori胃炎.
- 5年5个月的长度观察,包括H. pylori根除治疗前后的评估.
- 监测内镜检测结果和抗平底细胞抗体标位.
主要成果:
- 杆菌根除疗法导致了缩性变化的快速恶化,特别是在内镜上明显.
- 在根除后,抗parietal 细胞抗体标位显著增加 (1:320 到 1:1280).
- 在H. pylori治疗后,自身免疫性胃炎的活性似乎得到增强.
结论:
- 根除H. pylori可能会揭露或加速早期自身免疫性胃炎的活性.
- 这些发现表明,H. pylori可能会抑制AIG活动,或者AIG会独立地进展.
- 需要进一步的研究来澄清H. pylori和AIG之间的复杂相互作用.
更多相关视频
10:44One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
Published on: June 18, 2016
03:47Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
